Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics Inc (VVOS) provides innovative solutions for sleep-disordered breathing through its proprietary oral appliance therapy and integrated clinical protocols. This news hub offers investors and healthcare professionals direct access to official announcements, financial disclosures, and progress updates on the company's non-invasive treatment alternatives for obstructive sleep apnea.
Our curated collection features regulatory filings, partnership announcements, clinical trial updates, and technology developments. Users will find timely information about the Vivos System implementation, insurance coverage expansions, and research collaborations within the sleep medicine field.
The page organizes content by key categories including quarterly earnings reports, FDA communications, provider network growth, and peer-reviewed study publications. Each update maintains factual accuracy while highlighting the company's position in the $7 billion sleep apnea treatment market.
Bookmark this page for streamlined tracking of Vivos' progress in commercializing its oral appliance technology and expanding its licensed provider network. Check regularly for new developments in patient outcomes data and healthcare provider adoption rates across North America.
Vivos Therapeutics (NASDAQ: VVOS) has officially registered its products with Health Canada, enabling local dentists to provide comprehensive solutions for obstructive sleep apnea (OSA). The initiative aims to enhance patient outcomes through clinical screening, diagnosis, and treatment with Vivos’ oral appliances. Approximately 25,000 Canadian dentists are expected to utilize Vivos products, which have been effective for over 22,000 patients worldwide. The company plans to expand its manufacturing capacity in Canada to support this initiative, responding to strong demand for its innovative therapies.
Vivos Therapeutics, Inc. will present at the Benzinga Global Small Cap Conference on December 9, 2021, at 1:55 PM EST. The company's executives, including Chairman Kirk Huntsman and CFO Brad Amman, will discuss its innovative treatment for mild to moderate obstructive sleep apnea (OSA) using the Vivos System. This system is a non-surgical solution proven effective for over 22,000 patients worldwide. Interested investors can register for a free spectator pass and view the presentation online.
Vivos Therapeutics reported a 38% increase in Q3 revenue to $4.5 million, with a total of $12.5 million for the first nine months of 2021. Appliance sales surged by 33% in Q3, totaling 2,996 units sold. The company received FDA 510(k) clearance for its mmRNA device, enhancing reimbursement prospects. Despite a slight decrease in dentist enrollments due to COVID-19, strategic partnerships and new training facilities position Vivos for future growth. Gross margin decreased to 70% from 78% year-over-year, while cash reserves stand at $28.5 million.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q4 Virtual Investor Summit on November 17, 2021, at 11:45 am EST. The presentation features CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Investors can register for the event through the provided link and view a replay on Vivos’ website post-presentation. Vivos specializes in treatments for obstructive sleep apnea (OSA), promoting their innovative Vivos System as a non-surgical, cost-effective solution. The company has treated over 19,000 patients with their oral appliances.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its third-quarter financial results on November 15, 2021, after market close. The company will conduct a conference call at 5:00 p.m. ET on the same day to discuss the financial results and outline its growth strategy. Known for developing innovative treatments for obstructive sleep apnea, Vivos utilizes customized oral appliances in its Vivos System. The company has effectively treated over 19,000 patients globally, emphasizing its commitment to non-invasive solutions for OSA.
Vivos Therapeutics (NASDAQ: VVOS) will present at the Benzinga Global Small Cap Conference at 12:15 PM ET on October 27, 2021. The management team, including Chairman and CEO Kirk Huntsman and CFO Brad Amman, will discuss innovative treatments for mild to moderate obstructive sleep apnea (OSA) and snoring in adults. The conference runs from October 27-28, 2021. Interested investors can register for a free pass online. Vivos specializes in non-surgical treatments and has successfully treated over 19,000 patients worldwide.
Vivos Therapeutics (NASDAQ: VVOS) has announced the 3rd-annual Breathing Wellness Conference, set for October 20-23, 2021, in Las Vegas. The event aims to educate dentists and doctors about innovative treatments for patients suffering from obstructive sleep apnea (OSA) and snoring. Key speakers will discuss the implications of OSA on chronic health issues like heart disease and the latest advancements in dentofacial sleep medicine. Vivos strives to provide non-invasive solutions, differentiating itself from traditional treatments like CPAP machines.
Vivos Therapeutics (NASDAQ: VVOS) has announced a strategic collaboration with Candid Care Co. to create a comprehensive solution for diagnosing and treating obstructive sleep apnea (OSA) and providing orthodontic treatment. The partnership aims to integrate Candid's CandidPro aligner system with Vivos' innovative Vivos System. This alliance will focus on shared marketing efforts, educational resources, and specialized training to enhance patient outcomes. Both companies expect to increase market penetration and drive revenue growth through this collaboration, tapping into existing dental and healthcare networks in the U.S. and Canada.
Vivos Therapeutics (NASDAQ: VVOS) announced a collaboration with Candid Care to offer a comprehensive solution for obstructive sleep apnea (OSA) and orthodontic treatments. This partnership aims to combine Candid's clear aligners with Vivos' OSA treatment system, enhancing patient outcomes. The agreement includes joint marketing efforts, shared educational resources, and exploration of new research opportunities. The collaboration is expected to boost market penetration and revenue growth for both companies across North America.
Vivos Therapeutics (NASDAQ: VVOS) announced significant findings from a peer-reviewed study on its FDA-registered Vivos Guide, an intraoral device aimed at reducing pediatric tooth decay.
The study, led by Dr. Toshi Hart, demonstrated a 76.4% reduction in tooth decay risk at six months and 57.9% at twelve months for children using the device compared to a control group. The device encourages nasal breathing over mouth breathing, potentially increasing salivary factors that combat tooth decay.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
